Last reviewed · How we verify

NCT05662787: RESTORE ATK

BOLT Lithotripsy RESTORE ATK Trial

Completed NA Last updated 7 February 2025
What this trial tests

NA trial testing Intravascular Lithotripsy in Peripheral Arterial Disease in 97 participants. Completed in 30 July 2024.

Timeline
19 January 2023
Primary endpoint
20 June 2024
30 July 2024

Quick facts

Lead sponsorBolt Medical
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment97
Start date19 January 2023
Primary completion20 June 2024
Estimated completion30 July 2024
Sites11 locations across Austria, Croatia, Germany

Drugs / interventions tested

Conditions studied

Sponsor

Bolt Medical — full company profile →

Who can join

18 and older, any sex, with Peripheral Arterial Disease or Peripheral Vascular Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The RESTORE (ATK) above the knee study is a prospective, non- randomized, multi-center study for treatment of stenotic lesions with the Bolt Intravascular Lithotripsy System.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Intravascular Lithotripsy

Trials testing the same drug.

Other recruiting trials for Peripheral Arterial Disease

Currently open trials in the same condition.

Other Bolt Medical trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05662787.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing